share_log

Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Raises Price Target to $21

Cantor Fitzgerald Maintains Overweight on Amicus Therapeutics, Raises Price Target to $21

康特菲彻·菲茨杰认为爱美医疗仍然偏重,并将价格目标提高至21美元
Benzinga ·  2024/11/07 10:43  · 评级/大行评级

Cantor Fitzgerald analyst Kristen Kluska maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and raises the price target from $20 to $21.

康泰纳Fitzgerald 分析师Kristen Kluska 维持爱美医疗(纳斯达克:FOLD)的股票评级为超配,将价格目标从20美元上调至21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发